Wallace H. Coulter Department of Biomedical Engineering, Georgia Tech/Emory University, Atlanta, Georgia 30332, United States.
Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, Georgia 30332, United States.
ACS Macro Lett. 2024 Nov 19;13(11):1521-1530. doi: 10.1021/acsmacrolett.4c00634. Epub 2024 Oct 28.
Cell therapies, potent populations of cells used to treat disease and injury, can be strategically manufactured with biomaterial intervention to improve clinical translation. In this viewpoint, we discuss biomaterial design and integration into cell manufacturing steps to achieve three main goals: scale-up, phenotype control, and selection of potent cells. Material properties can be engineered to influence the cell-biomaterial interface and, therefore, impart desirable cell behavior such as growth, secretory activity, and differentiation. Future directions for the field should capitalize on the combinatorial design of biomaterial properties to yield highly specific and potent cell populations. Furthermore, future biomaterials could contribute to novel high-throughput cell separation technologies that can individually select the most therapeutically relevant cells within a produced batch.
细胞疗法是一种利用有治疗作用的细胞群体来治疗疾病和损伤的方法，可以通过生物材料干预进行策略性制造，以改善临床转化。在这个观点中，我们讨论了生物材料设计和整合到细胞制造步骤中，以实现三个主要目标：扩大规模、表型控制和选择有效细胞。材料性能可以进行工程设计，以影响细胞-生物材料界面，从而赋予细胞期望的行为，如生长、分泌活性和分化。该领域的未来方向应该利用生物材料性能的组合设计，产生高度特异和有效的细胞群体。此外，未来的生物材料可以为新型高通量细胞分离技术做出贡献，这些技术可以在生产批次中单独选择最具治疗相关性的细胞。
